SteadyMed Announces FDA Agreed Pathway to Trevyent NDA Resubmission Post author:Sam Post published:December 7, 2017 Post category:BioPharma No clinical trials are required for the NDA resubmission. Source: BioSpace You Might Also Like “An Unrelenting Disaster Zone”: Merck’s Alzheimer’s Drug Fails in Phase III February 13, 2018 Xenex Locks in $38 Million in Funding February 23, 2017 Cambridge's Exonics Therapeutics Scores $40M November 7, 2017
